Distinct metabolic architectures differentiate HLB-tolerant lemon and susceptible sweet orange
Frontiers in Plant Science · 11.08.2026 · 17
DOI: 10.3389/fpls.2026.1905341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Plant Science, online erschienen am 11.08.2026. Verfasst von Paul Gomes und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing, China. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Huanglongbing (HLB), caused by Candidatus Liberibacter asiaticus ( C Las), is a devastating citrus disease that severely threatens global citrus production, yet the metabolic mechanisms underlying citrus tolerance to HLB remain elusive. Citrus genotypes exhibit differential tolerance to HLB, with lemon ( Citrus limon ) showing greater resilience compared to susceptible sweet orange ( Citrus sinensis ). In this study, we integrated untargeted liquid chromatography-high resolution mass spectrometry metabolomics with a bootstrap-enhanced LASSO approach to characterize the metabolic responses of HLB-tolerant C. limon and susceptible C. sinensis to C Las infection. A total of 1,294 metabolites were identified. Bootstrap-enhanced LASSO identified stable discriminant metabolites (DMs) across four comparative frameworks, with phenylpropanoids (flavonols, furanocoumarins, and hydroxycinnamic acids) and limonoids being the most prominent DM classes. Lemon exhibited constitutively higher levels of kaempferol/quercetin-derived flavonols, linear furanocoumarins, monolignol glycosides, and limonoids compared to orange. While C Las infection induced quantitative changes in specific metabolic branches, the overall metabolic organization remained primarily determined by genotype. In the two cultivars examined, these results suggest that pre-existing metabolic configurations distinguish the tolerant lemon from the susceptible sweet orange and are associated with their contrasting HLB responses. This study provides robust metabolic signatures and candidate pathways for improving HLB tolerance through citrus breeding programs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Agricultural and Forestry Biosecurity, College of Plant Protection, Nanjing Agricultural University, Nanjing, China.
- Plant Protection Research Institute, Guangdong Academy of Agricultural Sciences, Key Laboratory of Green Prevention and Control on Fruits and Vegetables in South China Ministry of Agriculture and Rural Affairs, Guangdon…
- State Key Laboratory of Geohazard Prevention and Geoenvironment Protection, Chengdu University of Technology, Chengdu, China.
- College of Ecology and Environment, Chengdu University of Technology, Chengdu, China.
- Key Laboratory of Ecological Safety and Sustainable Development in Arid Lands, Xinjiang Institute of Ecology and Geography, Chinese Academy of Sciences, Urumqi, China.
- Department of Plant Pathology, Faculty of Agriculture and Environment, The Islamia University of Bahawalpur, Bahawalpur, Pakistan.
Zitieren
APA
Gomes, P., Cheng, B., Laffitte, B., Bilal, M. S., Aslam, M. N., Chen, Q., Wei, T., & Zhao, H. (2026). Distinct metabolic architectures differentiate HLB-tolerant lemon and susceptible sweet orange. Frontiers in Plant Science, 17. https://doi.org/10.3389/fpls.2026.1905341
Vancouver
Gomes P, Cheng B, Laffitte B, Bilal MS, Aslam MN, Chen Q, et al. Distinct metabolic architectures differentiate HLB-tolerant lemon and susceptible sweet orange. Frontiers in Plant Science. 2026;17. doi:10.3389/fpls.2026.1905341
BibTeX
@article{Gomes2026,
author = {Gomes, Paul and Cheng, Baoping and Laffitte, Benjamin and Bilal, Muhammad Saqib and Aslam, Muhammad Naveed and Chen, Qian and Wei, Taiyun and Zhao, Hongwei},
title = {Distinct metabolic architectures differentiate HLB-tolerant lemon and susceptible sweet orange},
journal = {Frontiers in Plant Science},
year = {2026},
volume = {17},
doi = {10.3389/fpls.2026.1905341}
}
EUVIMED